$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924007753 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$18.78M	$23.53M	$82.71M
YoY Change	9.24%	30.06%	28.52%
Cost Of Revenue	$1.728M	$2.286M	$9.361M
YoY Change	-23.71%	1.02%	22.3%
Gross Profit	$17.05M	$21.24M	$73.35M
YoY Change	14.24%	34.21%	29.36%
Gross Profit Margin	90.8%	90.28%	88.68%
Selling, General & Admin	$27.30M	$24.55M	$93.27M
YoY Change	11.54%	13.48%	12.6%
% of Gross Profit	160.08%	115.57%	127.16%
Research & Development	$15.49M	$11.30M	$45.61M
YoY Change	23.97%	-21.93%	-13.78%
% of Gross Profit	90.86%	53.2%	62.19%
Depreciation & Amortization	$100.0K	$190.0K	$800.0K
YoY Change	-50.0%	-19.49%	-11.11%
% of Gross Profit	0.59%	0.89%	1.09%
Operating Expenses	$42.79M	$35.85M	$138.9M
YoY Change	15.74%	-0.71%	2.32%
Operating Profit	-$25.74M	-$14.61M	-$65.54M
YoY Change	16.76%	-27.97%	-17.09%
Interest Expense	-$649.0K	-$2.860M	-$12.07M
YoY Change	-77.68%	1.53%	62.55%
% of Operating Profit
Other Income/Expense, Net	-$183.0K	-$4.693M	$838.0K
YoY Change	1120.0%	-7.64%	-103.89%
Pretax Income	-$32.23M	-$22.16M	-$98.32M
YoY Change	6.76%	-21.36%	-8.98%
Income Tax	$54.00K	$3.854M	$3.920M
% Of Pretax Income
Net Earnings	-$32.29M	-$26.02M	-$102.2M
YoY Change	6.86%	-7.9%	-6.34%
Net Earnings / Revenue	-171.91%	-110.57%	-123.61%
Basic Earnings Per Share	-$0.97		-$3.55
Diluted Earnings Per Share	-$0.97	-$0.72	-$3.55
COMMON SHARES
Basic Shares Outstanding	34.12M	30.87M	28.83M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$164.0M	$137.0M	$137.0M
YoY Change	152.17%	37.02%	37.02%
Cash & Equivalents	$131.4M	$95.00M	$95.00M
Short-Term Investments	$32.61M	$41.97M	$41.97M
Other Short-Term Assets	$11.31M	$11.10M	$11.10M
YoY Change	-12.7%	-6.82%	-6.82%
Inventory	$7.243M	$5.673M	$5.673M
Prepaid Expenses
Receivables	$14.16M	$15.44M	$15.44M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$196.8M	$169.2M	$169.2M
YoY Change	105.02%	31.25%	31.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$566.0K	$689.0K	$2.360M
YoY Change	-48.69%	-46.88%	-37.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$481.0K	$4.502M	$4.502M
YoY Change	-95.27%
Other Assets	$1.098M	$2.038M	$2.263M
YoY Change	-65.25%	-25.62%	-23.62%
Total Long-Term Assets	$3.814M	$9.125M	$9.125M
YoY Change	-77.54%	35.95%	35.95%
TOTAL ASSETS
Total Short-Term Assets	$196.8M	$169.2M	$169.2M
Total Long-Term Assets	$3.814M	$9.125M	$9.125M
Total Assets	$200.6M	$178.3M	$178.3M
YoY Change	77.57%	31.48%	31.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.259M	$6.514M	$6.514M
YoY Change	-10.18%	17.86%	17.86%
Accrued Expenses	$17.66M	$21.66M	$21.66M
YoY Change	10.06%	34.9%	34.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.34M	$31.21M	$31.21M
YoY Change	4.38%	30.51%	30.51%
LONG-TERM LIABILITIES
Long-Term Debt	$97.59M	$98.55M	$98.55M
YoY Change	-0.36%	1.04%	1.04%
Other Long-Term Liabilities	$116.8M	$113.8M	$113.8M
YoY Change	9.82%	9.88%	9.88%
Total Long-Term Liabilities	$97.59M	$98.55M	$212.3M
YoY Change	-0.36%	1.04%	5.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.34M	$31.21M	$31.21M
Total Long-Term Liabilities	$97.59M	$98.55M	$212.3M
Total Liabilities	$240.7M	$243.5M	$243.5M
YoY Change	4.88%	8.24%	8.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$711.6M	-$679.3M
YoY Change	17.17%	17.71%
Common Stock	$671.5M	$614.1M
YoY Change	36.82%	25.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$40.13M	-$65.21M	-$65.21M
YoY Change
Total Liabilities & Shareholders Equity	$200.6M	$178.3M	$178.3M
YoY Change	77.57%	31.48%	31.48%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$32.29M	-$26.02M	-$102.2M
YoY Change	6.86%	-7.9%	-6.34%
Depreciation, Depletion And Amortization	$100.0K	$190.0K	$800.0K
YoY Change	-50.0%	-19.49%	-11.11%
Cash From Operating Activities	-$31.74M	-$13.00M	-$76.38M
YoY Change	22.97%	-40.25%	-12.77%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$56.00K	$194.0K
YoY Change	-100.0%	330.77%	-23.62%
Acquisitions
YoY Change
Other Investing Activities	$13.52M	-$11.29M	-$759.0K
YoY Change	114.81%	-148.82%	-157.76%
Cash From Investing Activities	$13.52M	-$11.34M	-$953.0K
YoY Change	115.6%	-149.09%	-189.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$67.36M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$54.66M	40.00K	$116.9M
YoY Change	8045.6%	-99.84%	20.38%
NET CHANGE
Cash From Operating Activities	-$31.74M	-13.00M	-$76.38M
Cash From Investing Activities	$13.52M	-11.34M	-$953.0K
Cash From Financing Activities	$54.66M	40.00K	$116.9M
Net Change In Cash	$36.44M	-24.30M	$39.60M
YoY Change	-293.15%	-190.93%	272.37%
FREE CASH FLOW
Cash From Operating Activities	-$31.74M	-$13.00M	-$76.38M
Capital Expenditures	$0.00	$56.00K	$194.0K
Free Cash Flow	-$31.74M	-$13.05M	-$76.57M
YoY Change	22.86%	-40.03%	-12.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32490119
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32490119
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23129953
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23129953
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2023	dei	City Area Code CityAreaCode	646
CY2023	dei	Local Phone Number LocalPhoneNumber	768-9780
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	873000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	119000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-65212000	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38079
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IL
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	URGN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	190400000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34122087
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Florham Park, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95002000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55408000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	41966000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44556000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	821000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	813000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15443000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12704000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5673000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4325000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10281000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11101000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	169186000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	128907000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	225000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1671000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4502000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2038000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2740000	usd
CY2023Q4	us-gaap	Assets Assets	178311000	usd
CY2022Q4	us-gaap	Assets Assets	135619000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10814000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8257000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3860000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3276000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31212000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23916000	usd
CY2023Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	109722000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	98551000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97537000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3194000	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	3018000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	243523000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	224980000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	89000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	614035000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	487787000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-679348000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577104000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-107000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-65212000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178311000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	135619000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82713000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64357000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	9361000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	7654000	usd
CY2023	us-gaap	Gross Profit GrossProfit	73352000	usd
CY2022	us-gaap	Gross Profit GrossProfit	56703000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45614000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52906000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	93274000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	82838000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-65536000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-79041000	usd
CY2023	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21552000	usd
CY2022	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21559000	usd
CY2023	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	14715000	usd
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	8438000	usd
CY2023	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	3479000	usd
CY2022	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	1010000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98324000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108028000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3920000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1755000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102244000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102244000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	119000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-82000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102125000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-109865000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.55
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.81
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28834303
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22806812
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1511000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10580000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-82000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-89361000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9343000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	48700000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67358000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102244000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102244000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	802000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	924000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	870000	usd
CY2023	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	11504000	usd
CY2022	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	14007000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1034000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	498000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9343000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	10580000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1014000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1754000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	903000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	893000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1348000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	362000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2739000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	987000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-820000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3626000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-702000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1269000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4155000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	281000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2557000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1309000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-703000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-987000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1125000	usd
CY2023	urgn	Increase Decrease In Uncertain Tax Positions IncreaseDecreaseInUncertainTaxPositions	176000	usd
CY2022	urgn	Increase Decrease In Uncertain Tax Positions IncreaseDecreaseInUncertainTaxPositions	176000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76376000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87559000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	49832000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	63009000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	49073000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	64323000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	194000	usd
CY2023Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	4391000	usd
CY2022Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	618000	usd
CY2023Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1246000	usd
CY2022Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	2853000	usd
CY2023Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1049000	usd
CY2022Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1285000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	254000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-953000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1060000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	873000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1511000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	95783000	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	48700000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67358000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	160000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116931000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	97134000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	39602000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10635000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56221000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45586000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95823000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56221000	usd
CY2023	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	122000	usd
CY2022	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	2165000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a href="#" id="notes" title="notes"></a><span style="text-transform:uppercase;">Note <em style="font: inherit;">1</em><i> </i>– Business and Nature of Operations</span></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma, Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release <i>RTGel</i> technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-transform:uppercase;">Note<i> </i><em style="font: inherit;">2</em><i> </i>– Basis of Presentation</span></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-size: 10pt; margin: 0pt; font-family: Calibri;">The Company has experienced net losses since its inception and has an accumulated deficit of $679.3 million and $577.1 million as of <em style="font: inherit;"> December 31, 2023</em> and <em style="font: inherit;">2022</em>, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials. The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation. </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for the next <em style="font: inherit;">twelve</em> months from the date the financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments relating to the carrying amounts and classification of assets and liabilities that <em style="font: inherit;"> may </em>be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is expected to be impacted by its ability to raise additional capital to fund its operations, produce cash inflows from<i> Jelmyto</i> product sales and develop UGN-<em style="font: inherit;">102.</em> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company believes that absent sufficient proceeds received from equity, financing, or business development transactions, the Company will <em style="font: inherit;">not</em> have sufficient cash and cash equivalents to fund its operations beyond <em style="font: inherit;">one</em> year from the issuance of these financial statements. Accordingly, the Company will, over the next <em style="font: inherit;">twelve</em> months, require significant additional financing to continue its operations. In addition, there can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, on terms that are satisfactory to the Company, and in amounts sufficient to meet its needs. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Failure to successfully receive additional financing will require the Company to delay, limit or reduce product development and commercialization efforts.</p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-679300000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577100000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	141500000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Calibri; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6514000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5527000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-102244000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-109783000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28834303
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22806812
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.55
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.81
CY2023Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2752000	usd
CY2022Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1609000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	586000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	491000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16538000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12383000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2641000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	938000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	838000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72000	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	3479000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	1010000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4464000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4676000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2877000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2019000	usd
CY2023Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	7341000	usd
CY2022Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6695000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	46456000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	53000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	41000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	46468000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	56160000	usd
CY2023Q4	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax	53000	usd
CY2023Q4	urgn	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Losses Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossesBeforeTax	41000	usd
CY2023Q4	urgn	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	56172000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44663000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	107000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44556000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	22900000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	51670000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44556000	usd
CY2023Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	4502000	usd
CY2022Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	0	usd
CY2023Q4	us-gaap	Investments Investments	56172000	usd
CY2022Q4	us-gaap	Investments Investments	44556000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4641000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4447000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3952000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3150000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	900000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2022	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21559000	usd
CY2022	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	8349000	usd
CY2022Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	98923000	usd
CY2023	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	21552000	usd
CY2023	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	10753000	usd
CY2023Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	109722000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	934000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	975000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	224000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	224000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	73000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	65000	usd
CY2023	us-gaap	Lease Cost LeaseCost	783000	usd
CY2022	us-gaap	Lease Cost LeaseCost	816000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1671000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2452000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	844000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1586000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1169000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1195000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	122000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2165000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M23D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1021	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1025	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	938000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	825000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	58000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1821000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	158000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1663000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1146000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	904000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	788000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	49000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2887000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	360000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2527000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	49000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	49000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	251000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	49000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	300000	usd
CY2021Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1314000	usd
CY2022	urgn	Sales Reserve Accruals SalesReserveAccruals	13430000	usd
CY2022	urgn	Sales Reserve Utilization SalesReserveUtilization	-13307000	usd
CY2022Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1437000	usd
CY2023	urgn	Sales Reserve Accruals SalesReserveAccruals	23368000	usd
CY2023	urgn	Sales Reserve Utilization SalesReserveUtilization	-18834000	usd
CY2023Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	5971000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32500000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23100000
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	120000000	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3784480
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1009614
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	530000
CY2023	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	8.84
CY2023	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	17.94
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	410064
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	5.19
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	11.88
CY2023	urgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedFairValue	4300000	usd
CY2022	urgn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedFairValue	2200000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4400000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	22451000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17949000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11953000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	800000	usd
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2685796
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1831743
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1600000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9343000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10580000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2937000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	584000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	983000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1171000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3920000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1755000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	103566000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96434000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11485000	usd
CY2023Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	1345000	usd
CY2022Q4	urgn	Deferred Tax Assets Issuance Costs DeferredTaxAssetsIssuanceCosts	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1102000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1489000	usd
CY2023Q4	urgn	Deferred Tax Assets Rightofuse Asset DeferredTaxAssetsRightofuseAsset	-276000	usd
CY2022Q4	urgn	Deferred Tax Assets Rightofuse Asset DeferredTaxAssetsRightofuseAsset	-434000	usd
CY2023Q4	urgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	283000	usd
CY2022Q4	urgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	461000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2310000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1769000	usd
CY2023Q4	urgn	Deferred Tax Assets Depreciation Of Fixed Assets DeferredTaxAssetsDepreciationOfFixedAssets	-45000	usd
CY2022Q4	urgn	Deferred Tax Assets Depreciation Of Fixed Assets DeferredTaxAssetsDepreciationOfFixedAssets	-113000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	875000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	561000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	143566000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129601000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129601000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100619000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13965000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28982000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	143566000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129601000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98324000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-108028000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-22615000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24847000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	5704000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1052000	usd
CY2023	urgn	Effective Income Tax Rate Reconciliation Tax Credit Research Development And Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditResearchDevelopmentAndOrphanDrugAmount	1197000	usd
CY2022	urgn	Effective Income Tax Rate Reconciliation Tax Credit Research Development And Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditResearchDevelopmentAndOrphanDrugAmount	3586000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-689000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-263000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	176000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	176000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22898000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	28982000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-358000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	241000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3920000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1755000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-17900000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13300000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	452000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	419100000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3018000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2842000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	176000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	176000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3194000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3018000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3200000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1200000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd

Files In Submission

Name	View Source	Status
R21.htm	Edgar Link	pending
0001437749-24-007753-index-headers.html	Edgar Link	pending
0001437749-24-007753-index.html	Edgar Link	pending
0001437749-24-007753.txt	Edgar Link	pending
0001437749-24-007753-xbrl.zip	Edgar Link	pending
ex_599309.htm	Edgar Link	pending
ex_599310.htm	Edgar Link	pending
ex_599311.htm	Edgar Link	pending
ex_599312.htm	Edgar Link	pending
ex_636467.htm	Edgar Link	pending
ex_636478.htm	Edgar Link	pending
ex_636479.htm	Edgar Link	pending
ex_636699.htm	Edgar Link	pending
ex_636700.htm	Edgar Link	pending
ex_637873.htm	Edgar Link	pending
ex_638794.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipeline03112024.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20231231.xsd	Edgar Link	pending
urgn20231231_10k.htm	Edgar Link	pending
urgn-20231231_def.xml	Edgar Link	unprocessable
urgn-20231231_pre.xml	Edgar Link	unprocessable
urgn20231231_10k_htm.xml	Edgar Link	completed
urgn-20231231_lab.xml	Edgar Link	unprocessable
urgn-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2024 Q1 Form 10-K Financial Statement

#000143774924007753 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2024 Q1 Form 10-K Financial Statement

#000143774924007753 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn